ValuEngine Lowers Conatus Pharmaceuticals (CNAT) to Hold

ValuEngine lowered shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from a buy rating to a hold rating in a report published on Thursday.

A number of other analysts also recently issued reports on the stock. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the company a buy rating in a report on Monday, October 1st. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, July 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $11.80.

Shares of NASDAQ CNAT opened at $5.01 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.35 and a current ratio of 2.35. The firm has a market capitalization of $174.84 million, a price-to-earnings ratio of -8.21 and a beta of 1.38. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $8.77 million for the quarter, compared to the consensus estimate of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. On average, equities analysts forecast that Conatus Pharmaceuticals will post -0.61 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $142,000. Paloma Partners Management Co acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $547,000. Bank of America Corp DE lifted its position in shares of Conatus Pharmaceuticals by 75.7% in the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after buying an additional 60,604 shares during the last quarter. Alambic Investment Management L.P. lifted its position in shares of Conatus Pharmaceuticals by 207.0% in the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock valued at $1,133,000 after buying an additional 178,461 shares during the last quarter. Finally, MYDA Advisors LLC acquired a new stake in shares of Conatus Pharmaceuticals in the second quarter valued at approximately $154,000. Institutional investors own 33.50% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Further Reading: What is a Stop Order?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply